Table III.
Number of systemic adverse events in control and rhIL-2 trial group
| Systemic adverse events | Control (n) | rhIL-2 (n) |
|---|---|---|
| Hepatic injury | 4 | 2 |
| Kidney injury | 3 | 3 |
| Gastrointestinal reaction | 4 | 2 |
| Blood system influence | 0 | 3 |
| Auditory nerve damage | 0 | 0 |
| Optic nerve damage | 0 | 0 |
| Drug allergy | 0 | 0 |
| Nervous-mental system | 0 | 0 |
| Muscle and joint pain | 4 | 2 |
| Electrolyte abnormalities | 2 | 3 |
| Thyroid dysfunction | 1 | 0 |
| Total | 18 | 15 |
Fisher's exact test comparing rhIL-2 and control group. rhIL-2 – recombinant human interleukin-2.